Please assess the completion status of the following clinical trial:

Trial Title: EMMA-1 (Erbitux for Multiple Myeloma)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple myeloma diagnosed according to the Durie-criteria in stage II or III (Salmon and Durie)~* Measurable disease~* Refractory or relapsed disease after at least one line of treatment~* Male or female \>= 18 years of age~* Life expectancy \> 12 weeks~* ECOG performances status 0-2~* If of childbearing potential, willingness to use effective contraceptive method for the study duration and 6 months post-dosing.~* No surgery, radiotherapy or chemotherapy or any investigational agent within 30 days of study entry~* Signed written informed consent~Exclusion Criteria:~* Asecretory multiple myeloma~* Patients eligible and willing to undergo high dose chemotherapy followed by autologous stem cell transplantation~* Prior allogeneic transplantation~* Prior antibody or EGFR-pathway targeting therapy~* Severe cardiovascular disease like functionally restricting heart rhythm disturbance or heart malformation or severe hypertension, or cardiac insufficiency \> NYHA-II~* HIV Infection, Hepatitis B or C~* Brain disorders, psychiatric illness~* Insufficient bone marrow reserve (Leucocytes \< 1500/µl; Thrombocytes \< 50000/µl)~* Creatinine-Clearance \< 30 ml/min or Crea \> 3.0 mg/dl~* Bilirubin \> 2 mg/dl; ASAT, ALAT \> 100 U/l~* Pregnancy (absence confirmed by serum/urine beta-HCG) or breast-feeding~* FEV1 \< 50% of the reference value~* Active secondary malignancy~* Legal incapacity or limited legal capacity~* Having participated in another clinical trial or any investigational agent in the preceding 30 days~* Known allergic/hypersensitivity reaction to any compounds of the treatment~* Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent~* Known drug abuse/alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab + Dexamethasone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).